Gain Therapeutics (GANX) news
Recent news
GAN: We work with like-minded countries we can trust
GAN has emphasized its strategic focus on collaborating with like-minded countries and partners it can trust, reflecting a broader trend in global business and technology alliances. This approach aligns with the company’s recent expansion efforts, including a distribution agreement in Japan and…
AInvest Wire · 1d agoGalp - Q3 sales of oil products to clients 2.0 mln tonnes
AInvest Wire · 3d agoGain Therapeutics - To initiate phase 2 Rexaceract trial in Q1 2027 - SEC filing
Gain Therapeutics, Inc. (Nasdaq: GANX) has announced plans to initiate a Phase 2 clinical trial for its drug candidate, Rexaceract, in the first quarter of 2027, according to recent disclosures. The decision follows continued progress in the development of its lead therapy, GT-02287, for…
AInvest Wire · Oct 1, 2026Gain Therapeutics - Gene Mack to continue as president and CEO while serving as interim CFO - SEC filing
AInvest Wire · Sep 28, 2026Gain Therapeutics - Appoints Gene Mack as interim CFO effective Oct 1, 2026 - SEC filing
AInvest Wire · Sep 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.